Akari Therapeutics (NASDAQ:AKTX) has grabbed attention from the analysts, when it saw a value decrease of -1.69% or -0.1 points in the last trading session to close at $5.8. A total of 27.99 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 1.85 Million shares, while its relative volume stands at 20.14. Akari Therapeutics (NASDAQ:AKTX) has a market cap of $90.65 Million and the number of outstanding shares have been calculated 15.63 Million.
Shares of Akari Therapeutics (NASDAQ:AKTX) currently have an Average Brokerage Recommendation of 1, number of Recs in ABR is 2 while industry rank of the company by ABR is out of 255. Out of the analyst recommendations 1 rate Akari Therapeutics (NASDAQ:AKTX) stock a Buy, 1 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $5.5 on the stock, this valuation is based on 2 number of opinions. The most optimistic analyst sees the stock reaching $8 while the most conventional has $3 target price.
Akari Therapeutics (NASDAQ:AKTX) as of recent trade, has shown weekly upbeat performance of 220.69% which was maintained at 210.28% in 1-month period. During the past three months the stock gain 219.51%, bringing six months performance to 177.8%. Yearly performance of the stock shows a bullish trend of 151.08% while year-to-date (YTD) performance reflected 269.43% positive outlook.
While taking a glance at financials, we can look at a number of key indicators. Akari Therapeutics (NASDAQ:AKTX) has trailing twelve month Return on Assets of -119%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -207.2% and a Return on Investment of 0%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Akari Therapeutics (NASDAQ:AKTX) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Akari Therapeutics (NASDAQ:AKTX)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at -3.95.
The company’s quick ratio for most recent quarter is 2 along with current ratio for most recent quarter of 2. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.